Designing Tests That Predict Your Risk of Developing Cancer.
Proteocyte is developing a platform of solutions to predict a patient’s risk of developing cancer. Our platform identifies specific protein biomarkers that operate in combination with proprietary algorithms, advanced imaging and digital pathology enabling us to predict an individuals’ probability of non-cancerous lesions progressing to invasive cancer.
Founded in 2011, Proteocyte identified the need to provide healthcare professionals with more objective and quantifiable information that would significantly improve the outcome for their patients.
Proteocyte’s first product, Straticyte™, is a test that predicts the progression of pre-malignant lesions to invasive oral cancer. Straticyte enables healthcare professionals to customize patient management/treatment, improving outcomes for patients at risk for developing oral cancer, while reassuring those patients who have minimal to no risk of disease progression.
Chief Executive Officer
Chief Medical Officer
Chief Financial Officer
Principal Scientist, Straticyte Manager
Board of Directors
Clinical Advisory Board
MD, DMD, FACS, FACD, FRCS(Ed)
MD, DMD, FACS, FRCS
MD, DMD, FACS
MD, MSc, FRCSC
DDS, MD, PhD, FACS